Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace Wellbeing Acquisition and Clinical… Apr 30, 2021
In The Face of Emerging Research, Numinus’ Upcoming Phase One Trial Is All About Safety And Efficacy Apr 30, 2021
MINDCURE Shares Update on Strong Financial Position, Near Term Revenue Drivers and Timeline for iSTRYM’s Market… Apr 29, 2021
Mindset Pharma Announces Positive Preclinical Results of Its Proprietary Next Generation DMT & 5-MeO-DMT Compounds Apr 29, 2021
